Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Maurizio Fava |
Documentos disponibles escritos por este autor (21)
Refinar búsqueda
Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder / George I. Papakostas en Dialogues in Clinical Neuroscience, Año 2008 Vol.10 - No.4 (Diciembre)
[artículo]
Título : Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder Tipo de documento: texto impreso Autores: George I. Papakostas, Autor ; Maurizio Fava, Autor Fecha de publicación: 2022 Artículo en la página: pp. 439–451 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Depresión, Predecir, Antidepresivo, Resultado, Respuesta, Remisión Resumen: Major Depressive Disorder (MDD) is a prevalent illness that is frequently associated with significant disability, morbidity and mortality. Despite the development and availability of numerous treatment options for MDD, studies have shown that antidepressant monotherapy yields only modest rates of response and remission. Link: ./index.php?lvl=notice_display&id=28733
in Dialogues in Clinical Neuroscience > Año 2008 Vol.10 - No.4 (Diciembre) . - pp. 439–451[artículo] Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder [texto impreso] / George I. Papakostas, Autor ; Maurizio Fava, Autor . - 2022 . - pp. 439–451.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Dialogues in Clinical Neuroscience > Año 2008 Vol.10 - No.4 (Diciembre) . - pp. 439–451
Palabras clave: Depresión, Predecir, Antidepresivo, Resultado, Respuesta, Remisión Resumen: Major Depressive Disorder (MDD) is a prevalent illness that is frequently associated with significant disability, morbidity and mortality. Despite the development and availability of numerous treatment options for MDD, studies have shown that antidepressant monotherapy yields only modest rates of response and remission. Link: ./index.php?lvl=notice_display&id=28733 Rel-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder / Maurizio Fava en The American Journal of Psychiatry, Año 2022 Vol. 179 - No. 2 (Febrero)
[artículo]
Título : Rel-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder : a phase 2a randomized double-blind trial Tipo de documento: texto impreso Autores: Maurizio Fava, Autor ; Stephen M. Stahl, Autor ; Luca Pani, Autor Fecha de publicación: 2022 Artículo en la página: pp. 122-131 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastornos depresivos, Trastorno depresivo mayor, Neurología Resumen: The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episode. Link: ./index.php?lvl=notice_display&id=28331
in The American Journal of Psychiatry > Año 2022 Vol. 179 - No. 2 (Febrero) . - pp. 122-131[artículo] Rel-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder : a phase 2a randomized double-blind trial [texto impreso] / Maurizio Fava, Autor ; Stephen M. Stahl, Autor ; Luca Pani, Autor . - 2022 . - pp. 122-131.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2022 Vol. 179 - No. 2 (Febrero) . - pp. 122-131
Palabras clave: Trastornos depresivos, Trastorno depresivo mayor, Neurología Resumen: The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episode. Link: ./index.php?lvl=notice_display&id=28331 Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine / Maurizio Fava en Journal of Clinical Psychopharmacology, Año 2003 - Vol. 23 - No. 4 (Agosto)
[artículo]
Título : Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine Tipo de documento: texto impreso Autores: Maurizio Fava, Autor ; Patrick J. McGrath, Autor ; Wang Pui Sheu, Autor Fecha de publicación: 2023 Artículo en la página: pp. 365-369 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos, Trastorno depresivo mayor, Resistencia a los medicamentos, Fluoxetina, Morfolinas. Resumen: The aim of the present study was to evaluate the efficacy and safety of an immediate switch to reboxetine, a selective noradrenaline reuptake inhibitor (selective NRI), in patients with depression unresponsive to the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Link: ./index.php?lvl=notice_display&id=31011
in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 4 (Agosto) . - pp. 365-369[artículo] Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine [texto impreso] / Maurizio Fava, Autor ; Patrick J. McGrath, Autor ; Wang Pui Sheu, Autor . - 2023 . - pp. 365-369.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 4 (Agosto) . - pp. 365-369
Palabras clave: Antidepresivos, Trastorno depresivo mayor, Resistencia a los medicamentos, Fluoxetina, Morfolinas. Resumen: The aim of the present study was to evaluate the efficacy and safety of an immediate switch to reboxetine, a selective noradrenaline reuptake inhibitor (selective NRI), in patients with depression unresponsive to the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Link: ./index.php?lvl=notice_display&id=31011 The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study / Ella J. Daly en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 1 (Febrero)
[artículo]
Título : The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study Tipo de documento: texto impreso Autores: Ella J. Daly, Autor ; Madhukar H. Trivedi, Autor ; Maurizio Fava, Autor Fecha de publicación: 2022 Artículo en la página: pp. 31-38 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno depresivo mayor, Eventos adversos, Remisión Resumen: Little is known about the association between antidepressant treatment-emergent adverse events and symptom nonremission in major depressive disorder. The objective of the current analysis was to determine whether particular baseline symptoms or treatment-emergent symptoms (adverse events) during the first 2 weeks are associated with nonremission after 8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI). Link: ./index.php?lvl=notice_display&id=29405
in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 1 (Febrero) . - pp. 31-38[artículo] The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study [texto impreso] / Ella J. Daly, Autor ; Madhukar H. Trivedi, Autor ; Maurizio Fava, Autor . - 2022 . - pp. 31-38.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 1 (Febrero) . - pp. 31-38
Palabras clave: Trastorno depresivo mayor, Eventos adversos, Remisión Resumen: Little is known about the association between antidepressant treatment-emergent adverse events and symptom nonremission in major depressive disorder. The objective of the current analysis was to determine whether particular baseline symptoms or treatment-emergent symptoms (adverse events) during the first 2 weeks are associated with nonremission after 8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI). Link: ./index.php?lvl=notice_display&id=29405 Ziprasidone augmentation of escitalopram for major depressive disorder / George I. Papakostas en The American Journal of Psychiatry, Año 2015 - Vol. 172 - No. 12 (Diciembre)
[artículo]
Título : Ziprasidone augmentation of escitalopram for major depressive disorder : efficacy results from a randomized, double-blind, placebo-controlled study Tipo de documento: texto impreso Autores: George I. Papakostas, Autor ; Maurizio Fava, Autor ; Lee Baer, Autor Fecha de publicación: 2020 Artículo en la página: pp. 1251-1258 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos, Citalopram, Trastorno depresivo mayor, Terapia farmacológica. Resumen: The authors sought to test the efficacy of adjunctive ziprasidone in adults with nonpsychotic unipolar major depression experiencing persistent symptoms after 8 weeks of open-label treatment with escitalopram. Link: ./index.php?lvl=notice_display&id=22338
in The American Journal of Psychiatry > Año 2015 - Vol. 172 - No. 12 (Diciembre) . - pp. 1251-1258[artículo] Ziprasidone augmentation of escitalopram for major depressive disorder : efficacy results from a randomized, double-blind, placebo-controlled study [texto impreso] / George I. Papakostas, Autor ; Maurizio Fava, Autor ; Lee Baer, Autor . - 2020 . - pp. 1251-1258.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2015 - Vol. 172 - No. 12 (Diciembre) . - pp. 1251-1258
Palabras clave: Antidepresivos, Citalopram, Trastorno depresivo mayor, Terapia farmacológica. Resumen: The authors sought to test the efficacy of adjunctive ziprasidone in adults with nonpsychotic unipolar major depression experiencing persistent symptoms after 8 weeks of open-label treatment with escitalopram. Link: ./index.php?lvl=notice_display&id=22338 Zolpidem extended release improves sleep and next day symptoms in comorbid insomnia and generalized anxiety disorder / Maurizio Fava en Journal of Clinical Psychopharmacology, Año 2009 - Vol. 29 - No. 3 (Junio)Permalink